Cancer Nanomedicine: From Targeted Delivery to Combination Therapy
MetadataShow full item record
CitationXu, Xiaoyang, William Ho, Xueqing Zhang, Nicolas Bertrand, and Omid Farokhzad. 2015. “Cancer Nanomedicine: From Targeted Delivery to Combination Therapy.” Trends in molecular medicine 21 (4): 223-232. doi:10.1016/j.molmed.2015.01.001. http://dx.doi.org/10.1016/j.molmed.2015.01.001.
AbstractThe advent of nanomedicine marks an unparalleled opportunity to advance the treatment of a variety of diseases, including cancer. The unique properties of nanoparticles, such as large surface-to volume ratio, small size, the ability to encapsulate a variety of drugs, and tunable surface chemistry, gives them many advantages over their bulk counterparts. This includes multivalent surface modification with targeting ligands, efficient navigation of the complex in vivo environment, increased intracellular trafficking, and sustained release of drug payload. These advantages make nanoparticles a mode of treatment potentially superior to conventional cancer therapies. This article highlights the most recent developments in cancer treatment using nanoparticles as drug-delivery vehicles, including promising opportunities in targeted and combination therapy.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:26860036
- HMS Scholarly Articles